Organization · Venture Capital
OrbiMed
OrbiMed is a healthcare-focused investment firm based in New York City, managing approximately $19 billion in assets. The firm invests across the healthcare spectrum, from early-stage startups to large multinational companies, with a focus on biopharmaceuticals and medical technologies.
Overview
What OrbiMed does
What OrbiMed is
OrbiMed is a healthcare-focused investment firm based in New York City, managing approximately $19 billion in assets. The firm invests across the healthcare spectrum, from early-stage startups to large multinational companies, with a focus on biopharmaceuticals and medical technologies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1989
- Approximate age
- About 37 years
- Structured capabilities
- Funder
- Last reviewed
- April 23, 2026
Official channels
Find OrbiMed elsewhere
Open the official website or a supported primary organization account.
Capability profile
OrbiMed as a funder
Investment thesis
OrbiMed is a global investment firm dedicated to the healthcare sector, focusing on biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The firm employs a multi-strategy approach, investing across various stages from early-stage private companies to large multinational corporations.
Focus narrative
OrbiMed's investment strategy encompasses a wide range of healthcare sectors, including biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The firm targets investments across different stages, from early-stage private companies to established multinational corporations, ensuring a comprehensive approach to healthcare investment.
Value beyond capital
OrbiMed adds significant value to its portfolio companies through its extensive industry expertise, global network, and multi-strategy investment approach. The firm provides not only capital but also strategic guidance and support throughout the lifecycle of its investments, enabling companies to navigate challenges and seize growth opportunities.
Terms and economics
- Typical check
- $10,000,000–$30,000,000
- Sweet spot
- $20,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Digital Health · Medical Devices · Diagnostics
- Regions
- Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Notable portfolio companies include: Avenzo Therapeutics: A clinical-stage biotechnology company focused on developing next-generation oncology therapies. ADARx Pharmaceuticals: Developing a proprietary RNA targeting platform for therapeutics. Treeline Biosciences: Engaged in targeted oncology drug discovery. Mirador Therapeutics: Focused on precision medicine for immune-mediated inflammatory and fibrotic diseases. Adaptive Biotechnologies: A leader in measurable residual disease testing for lymphoid cancers, known for its product clonoSEQ®. Biokin: Developing innovative antibody-drug conjugates and multi-specific antibodies for cancer treatment.
Common questions
What to know about OrbiMed
Upseed classifies OrbiMed under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.